ArticleFrontiers in cellular and infection microbiology2026
Hypertension is associated with an increased risk of peritoneal dialysis-associated peritonitis: a retrospective cohort study.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Peritoneal dialysis-associated peritonitis (PDAP) remains a major complication of peritoneal dialysis (PD) and is a leading cause of hospitalization, technique failure, and mortality. Hypertension is highly prevalent among PD patients; however, its association with PDAP risk has not been well defined. Methods: We conducted a retrospective cohort study including adult PD patients followed between January 1, 2007, and December 31, 2024. Clinical characteristics, laboratory parameters, dialysis-related features, and PDAP events were systematically collected. Hypertension was defined by a documented diagnosis, long-term use of antihypertensive medications, or repeated blood pressure measurements ≥140/90 mmHg at baseline. The cumulative incidence of PDAP was assessed using cumulative incidence function (CIF) curves and Gray's test. Independent associations were evaluated using Fine-Gray competing risk models and multivariable logistic regression analyses. Results: Among 352 PD patients, 194 (55.1%) had hypertension. During a mean follow-up of 46.1 months, hypertensive patients exhibited a significantly higher cumulative incidence of PDAP. After multivariable adjustment, hypertension remained independently associated with a higher risk of PDAP in both Fine-Gray competing risk models (HR = 4.46, 95% CI 2.49-7.99, Conclusion: Baseline hypertension was independently associated with a higher risk of PDAP in patients undergoing PD. These findings highlight the potential importance of blood pressure status in PDAP risk stratification and long-term PD management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.